miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma

Oncotarget

Volumn 6, Issue 27, 2015, Pages 23480-23495

  Williams, Marissa ^a   Kirschner, Michaela B ^a,b,l   Cheng, Yuen Yee ^a   Hanh, Jacky ^a,c   Weiss, Jocelyn ^d   Mugridge, Nancy ^d   Wright, Casey M ^a   Linton, Anthony ^a,b,e   Kao, Steven C ^a,b,f   James B Edelman, J ^g   Vallely, Michael P ^g,h   McCaughan, Brian C ⁱ   Cooper, Wendy ^b,g   Klebe, Sonja ^j   Lin, Ruby C Y ^a,k   Brahmbhatt, Himanshu ^d   MacDiarmid, Jennifer ^d   van Zandwijk, Nico ^a,b   Reid, Glen ^a,b  

^a Asbestos Diseases Research Institute   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d EnGeneIC Ltd   (Australia)

^e Department of Microbiology and Infectious Diseases   (Australia)

^f Department of Medical Oncology Chris O'Brien Lifehouse ^*  (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h MACQUARIE UNIVERSITY   (Australia)

ⁱ Sydney Cardiothoracic Surgeons RPA Medical Centre   (Australia)

^j FLINDERS MEDICAL CENTRE   (Australia)

^k UNIVERSITY OF NEW SOUTH WALES   (Australia)

^l UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

Mesothelioma; MicroRNA; MiR 193a; Tumor suppressor

Indexed keywords

MICRORNA; MICRORNA 192; MICRORNA 193A 3P; MICRORNA 200; PROTEIN MCL 1; RNA; UNCLASSIFIED DRUG; MCL1 PROTEIN, HUMAN; MIRN192 MICRORNA, HUMAN; MIRN193 MICRORNA, HUMAN; MIRN200 MICRORNA, HUMAN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PLEURA MESOTHELIOMA; RETROSPECTIVE STUDY; RNA INTERFERENCE; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; CANCER TRANSPLANTATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; LUNG TUMOR; MESOTHELIOMA; METABOLISM; NECROSIS; PLEURA TUMOR; PROGNOSIS; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; MICE; MICRORNAS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NECROSIS; NEOPLASM TRANSPLANTATION; PLEURAL NEOPLASMS; PROGNOSIS; RNA INTERFERENCE; TRANSFECTION;

EID: 84943387521     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4346     Document Type: Article

References (67)

1. Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, Illei PB, Hussain S, Krug L, Zakowski MF, Rusch V, Olshen AB, Ladanyi M. Global gene expression profiling of pleural mesotheliomas:overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 2006;66:2970-2979.
2. Roe OD, Anderssen E, Helge E, Pettersen CH, Olsen KS, Sandeck H, Haaverstad R, Lundgren S, Larsson E. Genomewide profile of pleural mesothelioma versus parietal and visceral pleura:the emerging gene portrait of the mesothelioma phenotype. PloS one. 2009;4:e6554.
3. Roe OD, Anderssen E, Sandeck H, Christensen T, Larsson E, Lundgren S. Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets. Lung cancer. 2010;67:57-68.
4. Singhal S, Wiewrodt R, Malden LD, Amin KM, Matzie K, Friedberg J, Kucharczuk JC, Litzky LA, Johnson SW, Kaiser LR, Albelda SM. Gene expression profiling of malignant mesothelioma. Clinical cancer research :an official journal of the American Association for Cancer Research. 2003;9:3080-3097.
5. Balatti V, Maniero S, Ferracin M, Veronese A, Negrini M, Ferrocci G, Martini F, Tognon MG. MicroRNAs Dysregulation in Human Malignant Pleural Mesothelioma. J Thorac Oncol. 2011;6:844-851.
6. Guled M, Lahti L, Lindholm PM, Salmenkivi K, Bagwan I, Nicholson AG, Knuutila S. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma-A miRNA microarray analysis. Genes Chromosomes Cancer. 2009;48:615-623.
7. Ivanov SV, Goparaju CM, Lopez P, Zavadil J, TorenHaritan G, Rosenwald S, Hoshen M, Chajut A, Cohen D, Pass HI. Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem. 2010;285:22809-22817.
8. Reid G, Pel ME, Kirschner MB, Cheng YY, Mugridge N, Weiss J, Williams M, Wright C, Edelman JJ, Vallely MP, McCaughan BC, Klebe S, Brahmbhatt H, MacDiarmid JA, van Zandwijk N. Restoring expression of miR-16:a novel approach to therapy for malignant pleural mesothelioma. Annals of oncology :official journal of the European Society for Medical Oncology/ESMO. 2013; 24:3128-3135.
9. Benjamin H, Lebanony D, Rosenwald S, Cohen L, Gibori H, Barabash N, Ashkenazi K, Goren E, Meiri E, Morgenstern S, Perelman M, Barshack I, Goren Y, Edmonston TB, Chajut A, Aharonov R, et al. A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. J Mol Diagn. 2010;12:771-779.
10. Gee GV, Koestler DC, Christensen BC, Sugarbaker DJ, Ugolini D, Ivaldi GP, Resnick MB, Houseman EA, Kelsey KT, Marsit CJ. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int J Cancer. 2010;127:2859-2869.
11. Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, Murer B, Mutti L, Pierotti M, Gaudino G. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol. 2010;42:312-319.
12. Kirschner MB CY, Armstrong NJ, Lin RC, Kao SC, Linton A, Klebe S, McCaughan BC, van Zandwijk N, Reid G. MiR-Score:A novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. Molecular Oncology. 2014;accepted.
13. Pass HI, Goparaju C, Ivanov S, Donington J, Carbone M, Hoshen M, Cohen D, Chajut A, Rosenwald S, Dan H, Benjamin S, Aharonov R. hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer research. 2010;70:1916-1924.
14. Ueno T, Toyooka S, Fukazawa T, Kubo T, Soh J, Asano H, Muraoka T, Tanaka N, Maki Y, Shien K, Furukawa M, Sakaguchi M, Yamamoto H, Tsukuda K, Miyoshi S. Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma. Acta medica Okayama. 2014;68:23-26.
15. Linton A, Cheng YY, Griggs K, Kirschner MB, Gattani S, Srikaran S, Chuan-Hao Kao S, McCaughan BC, Klebe S, van Zandwijk N, Reid G. An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. British journal of cancer. 2014;110:510-519.
16. Kao SC, Yan TD, Lee K, Burn J, Henderson DW, Klebe S, Kennedy C, Vardy J, Clarke S, van Zandwijk N, McCaughan BC. Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. J Thorac Oncol. 2011;6:602-605.
17. Heller G, Weinzierl M, Noll C, Babinsky V, Ziegler B, Altenberger C, Minichsdorfer C, Lang G, Dome B, EndPfutzenreuter A, Arns BM, Grin Y, Klepetko W, Zielinski CC, Zochbauer-Muller S. Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clinical cancer research:an official journal of the American Association for Cancer Research. 2012;18:1619-1629.
18. Li Y, Gao L, Luo X, Wang L, Gao X, Wang W, Sun J, Dou L, Li J, Xu C, Wang L, Zhou M, Jiang M, Zhou J, Caligiuri MA, Nervi C, et al. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8, 21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. Blood. 2013;121:499-509.
19. Boni V, Bitarte N, Cristobal I, Zarate R, Rodriguez J, Maiello E, Garcia-Foncillas J, Bandres E. miR-12/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Molecular cancer therapeutics. 2010;9:2265-2275.
20. Lv L, Deng H, Li Y, Zhang C, Liu X, Liu Q, Zhang D, Wang L, Pu Y, Zhang H, He Y, Wang Y, Yu Y, Yu T, Zhu J. The DNA methylation-regulated miR-193a-3p dictates the multichemoresistance of bladder cancer via repression of SRSF2/PLAU/HIC2 expression. Cell death & disease. 2014;5:e1402.
21. Ma K, He Y, Zhang H, Fei Q, Niu D, Wang D, Ding X, Xu H, Chen X, Zhu J. DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Biol Chem. 2012;287:5639-5649.
22. Salvi A, Conde I, Abeni E, Arici B, Grossi I, Specchia C, Portolani N, Barlati S, De Petro G. Effects of miR-193a and sorafenib on hepatocellular carcinoma cells. Molecular cancer. 2013;12:162.
23. MacDiarmid JA, Mugridge NB, Weiss JC, Phillips L, Burn AL, Paulin RP, Haasdyk JE, Dickson KA, Brahmbhatt VN, Pattison ST, James AC, Al Bakri G, Straw RC, Stillman B, Graham RM, Brahmbhatt H. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer cell. 2007;11:431-445.
24. Kwon JE, Kim BY, Kwak SY, Bae IH, Han YH. Ionizing radiation-inducible microRNA miR-193a-3p induces apoptosis by directly targeting Mcl-1. Apoptosis :an international journal on programmed cell death. 2013; 18:896-909.
25. Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, CominAnduix B, Ribas A. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clinical cancer research :an official journal of the American Association for Cancer Research. 2014;20:3446-3457.
26. Zhang Y, Zhang J, Xu K, Xiao Z, Sun J, Xu J, Wang J, Tang Q. PTEN/PI3K/mTOR/B7-H1 signaling pathway regulates cell progression and immuno-resistance in pancreatic cancer. Hepato-gastroenterology. 2013;60:1766-1772.
27. Yu T, Li J, Yan M, Liu L, Lin H, Zhao F, Sun L, Zhang Y, Cui Y, Zhang F, Li J, He X, Yao M. MicroRNA-193a-3p and-5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway. Oncogene. 2014.
28. Chiang Y, Song Y, Wang Z, Liu Z, Gao P, Liang J, Zhu J, Xing C, Xu H. microRNA-192,-194 and-215 are frequently downregulated in colorectal cancer. Experimental and therapeutic medicine. 2012;3:560-566.
29. Geng L, Chaudhuri A, Talmon G, Wisecarver JL, Are C, Brattain M, Wang J. MicroRNA-192 suppresses liver metastasis of colon cancer. Oncogene. 2014;33:5332-40.
30. Karaayvaz M, Pal T, Song B, Zhang C, Georgakopoulos P, Mehmood S, Burke S, Shroyer K, Ju J. Prognostic significance of miR-215 in colon cancer. Clinical colorectal cancer. 2011;10:340-347.
31. Senanayake U, Das S, Vesely P, Alzoughbi W, Frohlich LF, Chowdhury P, Leuschner I, Hoefler G, Guertl B. miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. Carcinogenesis. 2012;33:1014-1021.
32. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 2008; 68:2094-2105.
33. Gao XN, Lin J, Li YH, Gao L, Wang XR, Wang W, Kang HY, Yan GT, Wang LL, Yu L. MicroRNA-193a represses c-kit expression and functions as a methylationsilenced tumor suppressor in acute myeloid leukemia. Oncogene. 2011;30:3416-3428.
34. Yang Y, Li X, Yang Q, Wang X, Zhou Y, Jiang T, Ma Q, Wang YJ. The role of microRNA in human lung squamous cell carcinoma. Cancer genetics and cytogenetics. 2010; 200:127-133.
35. Caramuta S, Egyhazi S, Rodolfo M, Witten D, Hansson J, Larsson C, Lui WO. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. The Journal of investigative dermatology. 2010; 130:2062-2070.
36. Santarelli L, Strafella E, Staffolani S, Amati M, Emanuelli M, Sartini D, Pozzi V, Carbonari D, Bracci M, Pignotti E, Mazzanti P, Sabbatini A, Ranaldi R, Gasparini S, Neuzil J, Tomasetti M. Association of MiR-12 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PloS one. 2011;6:e18232.
37. Fassina A, Cappellesso R, Guzzardo V, Dalla Via L, Piccolo S, Ventura L, Fassan M. Epithelial-mesenchymal transition in malignant mesothelioma. Modern pathology :an official journal of the United States and Canadian Academy of Pathology, Inc. 2012;25:86-99.
38. Wang J, Yang B, Han L, Li X, Tao H, Zhang S, Hu Y. Demethylation of miR-9-3 and miR-193a genes suppresses proliferation and promotes apoptosis in non-small cell lung cancer cell lines. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2013;32:1707-1719.
39. Kubo T, Toyooka S, Tsukuda K, Sakaguchi M, Fukazawa T, Soh J, Asano H, Ueno T, Muraoka T, Yamamoto H, Nasu Y, Kishimoto T, Pass HI, Matsui H, Huh NH, Miyoshi S. Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clinical cancer research :an official journal of the American Association for Cancer Research. 2011;17:4965-4974.
40. Shen J, Xia W, Khotskaya YB, Huo L, Nakanishi K, Lim SO, Du Y, Wang Y, Chang WC, Chen CH, Hsu JL, Wu Y, Lam YC, James BP, Liu X, Liu CG, et al. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature. 2013; 497:383-387.
41. Klabatsa A, Sheaff MT, Steele JP, Evans MT, Rudd RM, Fennell DA. Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM). Lung cancer. 2006;51:53-59.
42. Edwards JG, Swinson DE, Jones JL, Waller DA, O'Byrne KJ. EGFR expression:associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung cancer. 2006;54:399-407.
43. Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P, Pellegrini C, Cordani N, Vaira V, Alloisio M, Rizzi A, Bosari S, Roncalli M. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung cancer. 2006;51:207-215.
44. Kawai S, Amano A. BRCA1 regulates microRNA biogenesis via the DROSHA microprocessor complex. The Journal of cell biology. 2012;197:201-208.
45. Busacca S, Sheaff M, Arthur K, Gray SG, O'Byrne KJ, Richard DJ, Soltermann A, Opitz I, Pass H, Harkin DP, Quinn JE, Fennell DA. BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. The Journal of pathology. 2012;227:200-208.
46. Ory B, Ramsey MR, Wilson C, Vadysirisack DD, Forster N, Rocco JW, Rothenberg SM, Ellisen LW. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. The Journal of clinical investigation. 2011;121:809-820.
47. Nakano H, Yamada Y, Miyazawa T, Yoshida T. Gain-offunction microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells. International journal of oncology. 2013;42:1875-1882.
48. Lam LT, Lu X, Zhang H, Lesniewski R, Rosenberg S, Semizarov D. A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax). Molecular cancer therapeutics. 2010;9:2943-2950.
49. Truini A, Coco S, Alama A, Genova C, Sini C, Dal Bello MG, Barletta G, Rijavec E, Burrafato G, Boccardo F, Grossi F. Role of microRNAs in malignant mesothelioma. Cell Mol Life Sci. 2014;71:2865-2878.
50. Lin RCYvZ N, Reid G. MicroRNA Therapeutics-Back in Vogue? J Investig Genomics. 2015;2:00012.
51. Gaafar R, Bahnassy A, Abdelsalam I, Kamel MM, Helal A, Abdel-Hamid A, Eldin NA, Mokhtar N. Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. Lung cancer. 2010;70:43-50.
52. Okuda K, Sasaki H, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y. Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma. J Cancer Res Clin Oncol. 2008; 134:1105-1111.
53. Rena O, Boldorini LR, Gaudino E, Casadio C. Epidermal growth factor receptor overexpression in malignant pleural mesothelioma:prognostic correlations. J Surg Oncol. 2011; 104:701-705.
54. Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res. 2014; 74:2907-2912.
55. Birnie KA, Yip YY, Ng DC, Kirschner MB, Reid G, Prele CM, Musk AW, Lee YG, Thompson PJ, Mutsaers SE, Badrian B. Loss of mir-223 and JNK Signalling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma. Mol Cancer Res. 2015.
56. Bader AG. miR-34-a microRNA replacement therapy is headed to the clinic. Frontiers in genetics. 2012;3:120.
57. van Zandwijk NP n, Kao S, Clarke S, Lee A, Brahmbhatt H, Macdiarmid J, Pattison S, Leslie F, Huynh Y, Linton A, Reid G. MesomiR 1:A Phase I study of TargomiRs in patients with refractory malignant pleural mesothelioma (MPM) and lung cancer (NSCLC). Annals of oncology:official journal of the European Society for Medical Oncology/ESMO. 2015;26:ii16.
58. Kao SC, Lee K, Armstrong NJ, Clarke S, Vardy J, van Zandwijk N, Reid G, Burn J, McCaughan BC, Henderson DW, Klebe S. Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology. 2011;43:128-132.
59. Relan V, Morrison L, Parsonson K, Clarke BE, Duhig EE, Windsor MN, Matar KS, Naidoo R, Passmore L, McCaul E, Courtney D, Yang IA, Fong KM, Bowman RV. Phenotypes and karyotypes of human malignant mesothelioma cell lines. PloS one. 2013;8:e58132.
60. Kryeziu K, Jungwirth U, Hoda MA, Ferk F, Knasmuller S, Karnthaler-Benbakka C, Kowol CR, Berger W, Heffeter P. Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair. Molecular cancer therapeutics. 2013;12:1073-1084.
61. Marklund SL, Westman NG, Lundgren E, Roos G. Copper-and zinc-containing superoxide dismutase, manganese-containing superoxide dismutase, catalase, and glutathione peroxidase in normal and neoplastic human cell lines and normal human tissues. Cancer Res. 1982; 42:1955-1961.
62. Schmitter D, Lauber B, Fagg B, Stahel RA. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines:interleukin-6 production as a common feature. Int J Cancer. 1992;51:296-301.
63. Reid G, Wallant NC, Patel R, Antonic A, SaxonAliifaalogo F, Cao H, Webster G, Watson JD. Potent subunitspecific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase. Journal of RNAi and gene silencing :an international journal of RNA and gene targeting research. 2009;5:321-330.
64. Cheng YY, Kirschner MB, Cheng NC, Gattani S, Klebe S, Edelman JJ, Vallely MP, McCaughan BC, Jin HC, van Zandwijk N, Reid G. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma. Journal of thoracic oncology :official publication of the International Association for the Study of Lung Cancer. 2013;8:1317-1328.
65. Kirschner MB, Cheng YY, Badrian B, Kao SC, Creaney J, Edelman JJ, Armstrong NJ, Vallely MP, Musk AW, Robinson BW, McCaughan BC, Klebe S, Mutsaers SE, van Zandwijk N, Reid G. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. Journal of thoracic oncology :official publication of the International Association for the Study of Lung Cancer. 2012;7:1184-1191.
66. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ:25 years of image analysis. Nat Methods. 2012; 9:671-675.
67. Edge S, Byrd D.R, Comptom C.C, Fritz A.G, Greene F.L, Trotti A. 2010;AJCC Cancer Staging Manual:Springer, New York.